

Cover Story
NCI Director's Report
By Alexandria Carolan and Paul Goldberg
Amid the gridlock that has seized Washington, NCI faces a grim and disturbing FY2024, the institute’s Principal Deputy Director Douglas R. Lowy said at the annual meeting of the Association of American Cancer Institutes.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Bhattacharya cancels NIH all-hands meeting
- In the Headlines: “There’s no one to stand up for NCI right now.”
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies